Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'

Kirchhof, Paulus; Bax, Jeroen J.; Blomstrom-Lundquist, Carina; Calkins, Hugh; Camm, A. John; Cappato, R.; Cosío, Francisco G.; Crijns, Harry J.G.M.; Diener, H.‐C.; Goette, Andreas; Israel, Carsten W.; Kuck, Karl Heinz; Lip, Gregory Y. H.; Nattel, Stanley; Page, Richard L.; Ravens, Ursula; Schotten, Ulrich; Steinbeck, Gerhard; Vardas, Panos; Waldo, Albert L.; Wegscheider, Karl; Willems, Stephan; Breithardt, Günter

doi:10.1093/europace/eup124

Cited by 108 publications

(59 citation statements)

References 260 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, the use of daily tele-ECGs is in accordance with a recommended monitoring strategy in AF trials. 31 It is conceivable, however, that long-term therapy with ARBs over several years may produce a long-term antiarrhythmic effect in patients with AF without structural heart disease. The survival curves reveal trends that suggest possible differences beyond the time interval studied (Figure 3).…”

Section: Limitationsmentioning

confidence: 99%

Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial

Goette

Schön

Kirchhof

et al. 2012

Circ: Arrhythmia and Electrophysiology

164

View full text Add to dashboard Cite

Background— Unlike antiarrhythmic drugs, the safety and beneficial effects of angiotensin II receptor blockade (ARB) in patients with structural heart disease is well established. The clinical efficacy of ARBs to prevent atrial fibrillation (AF) so far only has been shown in patients with structural heart disease. Here, we report the primary outcome of the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) trial, which investigated the effect of olmesartan medoxomil compared with placebo on AF burden in patients with paroxysmal AF without structural heart disease. Methods and Results— The ANTIPAF trial was a prospective, randomized, placebo-controlled, multicenter trial analyzing the AF burden (percentage of days with documented episodes of paroxysmal AF) during a 12-month follow-up as the primary study end point. Four hundred thirty patients with documented paroxysmal AF without structural heart disease were randomized to placebo or 40 mg olmesartan per day. Concomitant therapy with ARBs, angiotensin-converting enzyme inhibitors, and antiarrhythmic drugs was prohibited. Patients were followed using daily transtelephonic ECG (tele-ECG) recordings independent of symptoms. The intention-to-treat population of the trial encompassed 425 patients (placebo group, n=211; olmesartan group, n=214). A total of 87 818 tele-ECGs were analyzed in these patients during follow-up (placebo group, 44 888 ECGs; olmesartan group, 42 930 ECGs). Thus, a mean of 207 tele-ECGs were recorded per patient. The primary end point (AF burden) was not different between the 2 groups ( P =0.770). Secondary outcome parameters, including quality of life, also were not different. In particular, time to first AF recurrence, time to persistent AF, and number of hospitalizations were not different between the 2 groups. The time to prescription of recovery medication (amiodarone) was the only parameter showing an intergroup difference, with earlier prescription of amiodarone in the placebo group ( P =0.022). Conclusions— One year of ARB therapy per se does not reduce the number of AF episodes in patients with documented paroxysmal AF without structural heart disease. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00098137.

show abstract

Section: Limitationsmentioning

confidence: 99%

Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial

Goette

Schön

Kirchhof

et al. 2012

Circ: Arrhythmia and Electrophysiology

164

View full text Add to dashboard Cite

show abstract

“…Это позволяет за счет предсердно-селективной блока-ды Na + -каналов эффективно подавлять ФП, не вызывая желудочковую аритмию. В предсердиях, в дополнение к блокаде INaL и IKr, ранолазин замедляет пик потока быстрых Na + -каналов, а в желудочках -ингибирует INaL [27]. Описанное действие ранолазина представляется перспективным для лечения ФП, особенно у пациентов с ХСН, поскольку препарат минимизирует патологи-ческие последствия натриевой перегрузки.…”

Section: результаты и обсуждениеunclassified

Cardioprotective therapy in patients with atrial fibrillation and heart failure with preserved ejection fraction (Pilot study)

Tatarskiy¹,

Казеннова²,

Arutyunov³

2017

RHJ

View full text Add to dashboard Cite

“…20 In another study, the prevalence of atrial fibrillation in patients who experienced first ever ischemic stroke was found to be 24.6%. 21 The proposed mechanism that how atrial fibrillation causes ischemic stroke is explained by its association with thrombosis in the left atrium or left atrial appendage due to stasis of blood, 22 embolization of these thrombi ultimately results in ischemic stroke.…”

mentioning

confidence: 94%

Ischemic Stroke

Alam¹,

Rizvi²,

Alam³

et al. 2018

TPMJ

View full text Add to dashboard Cite

ABSTRACT… Objectives: To determine the frequency and contributing factors of atrial fibrillation in patients with first ischemic stroke. Methodology: This study included 150 patients with first acute ischemic stroke. All the patients had electrocardiography to detect the presence of atrial fibrillation. The patients were also labeled for risk factors like hypertension, congestive heart failure, smoking, and hyperthyroidism, etc. Setting: Mayo Hospital Lahore. Duration of Study: 1 st January 2013 to 30 th June 2013. Type: Descriptive Cross Sectional. Results: Atrial fibrillation was present among 22 (14.6%) patients. Among patients with atrial fibrillation, smoking, congestive heart failure and hypertension were the most frequent risk factors which were present in 11 (50%), 6 (27%), and 5 (22.7%) patients, respectively. Conclusion: Frequency of atrial fibrillation among patients with first ischemic stroke was high. Smoking, congestive heart failure and history of coronary artery bypass grafting are frequent risk factors. Key words:Ischemic Stroke; Atrial Fibrillation; Contributing Factors.

show abstract

Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'

Cited by 108 publications

References 260 publications

Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial

Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial

Cardioprotective therapy in patients with atrial fibrillation and heart failure with preserved ejection fraction (Pilot study)

Ischemic Stroke

Contact Info

Product

Resources

About